Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials Article

ESI Most Cited Paper Industry Collaboration International Collaboration

Bachert, Claus; Han, Joseph K.; Desrosiers, Martin; Hellings, Peter W.; Amin, Nikhil; Lee, Stella E.; Mullol, Joaquim; Greos, Leon S.; Bosso, John V.; Laidlaw, Tanya M.; Cervin, Anders U.; Maspero, Jorge F.; Hopkins, Claire; Olze, Heidi; Canonica, G. Walter; Paggiaro, Pierluigi; Cho, Seong H.; Fokkens, Wytske J.; Fujieda, Shigeharu; Zhang, Mei; Lu, Xin; Fan, Chunpeng; Draikiwicz, Steven; Kamat, Siddhesh A.; Khan, Asif; Pirozzi, Gianluca; Patel, Naimish; Graham, Neil M. H.; Ruddy, Marcella; Staudinger, Heribert; Weinreich, David; Stahl, Neil; Yancopoulos, George D.; Mannent, Leda P.